CA-XPRIZE
23.6.2021 19:32:08 CEST | Business Wire | Press release
XPRIZE , the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, and IBM Watson , IBM’s AI technology for business, today announced the Grand Prize Winner in the $5M IBM Watson AI XPRIZE Challenge . First launched in 2016, the five-year global competition looked to accelerate adoption of artificial intelligence (AI) technologies and spark creative, innovative and audacious demonstrations of the technology that are truly scalable to solve societal grand challenges.
Winning first place honors is Zzapp Malaria , in second place is Aifred Health , followed by Marinus Analytics . These finalists were selected out of a pool of 10 semifinalists following presentations of their solutions to a panel of judges during an event held at TED headquarters in New York City last year. A $3 million grand prize, $1 million second place prize, and $500k third place prize will be awarded to the teams. In total, over 150 teams throughout the world joined the competition.
"After five years of hard work and dedication, XPRIZE is thrilled to announce Zzapp Malaria as the grand prize winner of IBM Watson AI XPRIZE,” said Anousheh Ansari, CEO of XPRIZE. “Zzapp Malaria, Aifred Health and Marinus Analytics are on the forefront of AI advancement, and we are looking forward to seeing firsthand the positive impact they will have on our future.”
"Each of the three finalists of the IBM Watson AI XPRIZE showcase what's possible when the power of AI is used to address some of the world’s toughest challenges,” said Daniel Hernandez, General Manager, IBM Data and AI. “It’s inspiring to witness how the AI technologies we developed at IBM help these organizations realize and scale their good tech solutions to drive positive societal change.”
Based out of Tel Aviv, Israel, Zzapp Malaria is committed to malaria elimination. The team’s AI technology is geared towards tackling the main challenges faced by malaria elimination campaigns by creating custom models, built with tools like IBM Watson Studio for Cloud Pak for Data, to predict the number of small water bodies caused by weather, enabling it to optimize the timing for launching larviciding operations.
- Marinus Analytics (based out of Pittsburgh, PA): A woman-owned company founded in 2014 out of Carnegie Mellon Robotics that is driven by a single social mission: To fight human trafficking. Their solution, Traffic Jam, is a suite of analytics tools that saves hours and sometimes days of investigative time to find traffickers and recover victims by quickly turning big data into actionable intelligence. Marinus Analytics has used IBM Watson Discovery and IBM Watson Assistant to extend their Traffic Jam application, aiding investigation into financial fraud and the illicit flow of proceeds to international crime groups.
- Aifred Health (based out of Montreal, Canada): A digital health company focused on clinical decision support in mental health, starting with depression. The team’s solution uses AI to learn from thousands of patients to help tailor treatment, reducing the time it takes for a patient to reach remission. IBM Watson Health is providing Aifred Health with millions of records of observational depression data to improve their ML models.
To determine the winner, XPRIZE AI convened a global jury of representatives from around the world. The jury evaluated each team based on their performance in the following four dimensions: achieved technical impact, evidenced real-world impact, scalability of real-world impact, and ethics and safety.
The winning teams were announced today in partnership with WIRED during the IBM Watson AI XPRIZE’s AI For Good fireside chat featuring Anousheh Ansari, CEO of XPRIZE, and Seth Dobrin, IBM’s Chief AI Officer. The two discussed the challenge and the importance of AI for the future of humanity. As part of their partnership with WIRED, XPRIZE opened up a public vote for the Most Inspiring Team, and Zzapp Malaria was selected as the winner. You can watch the full fireside chat and view additional content via WIRED’s content hub linked here.
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100M XPRIZE Carbon Removal, $15M XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE and $5 Million XPRIZE Rapid Reskilling. For more information, visit xprize.org.
About IBM Watson
Watson is IBM’s AI technology for business, helping organizations to better predict and shape future outcomes, automate complex processes, and optimize employees’ time. Watson has evolved from an IBM Research project, to experimentation, to a scaled, open set of products that run anywhere. With more than 40,000 client engagements, Watson is being applied by leading global brands across a variety of industries to transform how people work. To learn more, visit: https://www.ibm.com/watson .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005848/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom